PMID- 12705995
OWN - NLM
STAT- MEDLINE
DCOM- 20030814
LR  - 20190826
IS  - 0302-2838 (Print)
IS  - 0302-2838 (Linking)
VI  - 43
IP  - 5
DP  - 2003 May
TI  - Centrosome hyperamplification and chromosomal instability in bladder cancer.
PG  - 505-15
AB  - OBJECTIVE: Chromosomal instability (CIN) is a common feature of malignant tumors. 
      Centrosome hyperamplification (CH) occurs frequently in human cancers, and may be 
      a contributing factor in CIN. In this study, we investigated the relationship 
      between CH and CIN in bladder cancer. METHODS: Clinical samples obtained by 
      transurethral resection from 22 patients with bladder cancer were examined 
      (histological grade G1, 5 cases; G2, 6 cases; G3, 11 cases). CH was evaluated by 
      immunohistochemistry using anti-pericentrin antibody. CIN was evaluated by 
      fluorescence in situ hybridization (FISH). FISH probes for pericentromeric 
      regions of chromosomes 3, 7, and 17 were hybridized to touch preparations of 
      nuclei from frozen tissues. We also analyzed the centrosome replication cycle of 
      bladder cancer by laser scanning cytometry (LSC). RESULTS: Of the 22 cases 
      examined, 18 (81.8%) had centrosome hyperamplification: CH 0, 4 cases (18.1%); CH 
      I, 5 cases (22.7%); CH II, 5 cases (22.7%); CH III, 8 cases (36.4%). The grade of 
      CH was directly proportional to the histological grade (p=0.03, chi(2) test). LSC 
      analysis showed that the centrosome replication cycle was well regulated in 
      pathologically low-grade bladder cancer, which did not have chromosomal 
      instability. In contrast, we found marked variability of centrosomes in 
      pathologically high-grade bladder cancer, which had chromosomal instability. CH 
      and CIN were both detected in pathologically high-grade tumors. The grade of CH 
      was directly proportional to the CIN grade (p=0.0079, chi(2) test). CONCLUSION: 
      The results of the present study suggest that CH may be involved in CIN in 
      bladder cancer.
FAU - Kawamura, K
AU  - Kawamura K
AD  - Department of Urology, Kanazawa Medical University, 1-1 Daigaku Uchinada, 
      920-0293, Ishikawa, Japan. kawamura@kanazawa-med.ac.jp
FAU - Moriyama, M
AU  - Moriyama M
FAU - Shiba, N
AU  - Shiba N
FAU - Ozaki, M
AU  - Ozaki M
FAU - Tanaka, T
AU  - Tanaka T
FAU - Nojima, T
AU  - Nojima T
FAU - Fujikawa-Yamamoto, K
AU  - Fujikawa-Yamamoto K
FAU - Ikeda, R
AU  - Ikeda R
FAU - Suzuki, K
AU  - Suzuki K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Eur Urol
JT  - European urology
JID - 7512719
RN  - 0 (Antigens)
RN  - 0 (pericentrin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens/analysis
MH  - Centrosome/*pathology/physiology
MH  - *Chromosome Aberrations
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Ploidies
MH  - Urinary Bladder Neoplasms/*genetics/pathology
MH  - Urothelium/pathology
EDAT- 2003/04/23 05:00
MHDA- 2003/08/15 05:00
CRDT- 2003/04/23 05:00
PHST- 2003/04/23 05:00 [pubmed]
PHST- 2003/08/15 05:00 [medline]
PHST- 2003/04/23 05:00 [entrez]
AID - S0302283803000563 [pii]
AID - 10.1016/s0302-2838(03)00056-3 [doi]
PST - ppublish
SO  - Eur Urol. 2003 May;43(5):505-15. doi: 10.1016/s0302-2838(03)00056-3.